Lineage Cell Therapeutics (LCTX) Gross Profit Growth (3y) (2014 - 2026)
Lineage Cell Therapeutics (LCTX) Gross Profit Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 54.36% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 7.16% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.86% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 80.64% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | -8.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.71% |
| Dec 31, 2025 | 53.38% |
| Sep 30, 2025 | 9.98% |
| Jun 30, 2025 | -14.35% |
| Mar 31, 2025 | -33.83% |
| Dec 31, 2024 | 41.20% |
| Sep 30, 2024 | 42.79% |
| Jun 30, 2024 | 52.18% |
| Mar 31, 2024 | 68.97% |
| Dec 31, 2023 | 96.62% |
| Sep 30, 2023 | 31.93% |
| Jun 30, 2023 | 115.17% |
| Mar 31, 2023 | 75.42% |
| Dec 31, 2022 | 17.49% |
| Sep 30, 2022 | 82.71% |
| Jun 30, 2022 | 86.20% |
| Mar 31, 2022 | 80.54% |
| Dec 31, 2021 | 10.94% |
| Sep 30, 2021 | 10.71% |
| Jun 30, 2021 | -45.88% |